We are live on ! Find out more
AKYA

Akoya BioSciences

Delisted

AKYA was delisted on the 7th of July, 2025.

65 hedge funds and large institutions have $80.5M invested in Akoya BioSciences in 2023 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 25 increasing their positions, 21 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

9,850% more call options, than puts

Call options by funds: $199K | Put options by funds: $2K

43% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 7

19% more repeat investments, than reductions

Existing positions increased: 25 | Existing positions reduced: 21

8% more capital invested

Capital invested by funds: $74.9M → $80.5M (+$5.65M)

5% more funds holding

Funds holding: 6265 (+3)

2.59% less ownership

Funds ownership: 32.83%30.24% (-2.6%)

50% less funds holding in top 10

Funds holding in top 10: 21 (-1)

Holders
65
Holders Change
+3
Holders Change %
+4.84%
% of All Funds
0.95%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.01%
New
10
Increased
25
Reduced
21
Closed
7
Calls
$199K
Puts
$2K
Net Calls
+$197K
Net Calls Change
+$31K
Name Holding Trade Value Shares
Change
Change in
Stake
BWLSA
1
Blue Water Life Science Advisors
California
$22.9M
Goldman Sachs
2
Goldman Sachs
New York
$8.01M -$36.8K -8,848 -47%
PCH
3
Polar Capital Holdings
United Kingdom
$7.71M
Vanguard Group
4
Vanguard Group
Pennsylvania
$6.87M +$240K +57,762 +4%
BlackRock
5
BlackRock
New York
$6.7M -$302K -72,770 -5%
UIC
6
Uniplan Investment Counsel
Wisconsin
$3.42M +$494K +118,963 +21%
PHP
7
Parkman Healthcare Partners
Connecticut
$3.29M +$620K +149,164 +28%
BOTOTLSJU
8
Board of Trustees of The Leland Stanford Junior University
California
$3.03M -$4 -1 -0%
SW
9
SVB Wealth
Massachusetts
$2.51M
Geode Capital Management
10
Geode Capital Management
Massachusetts
$2.43M +$133K +32,094 +7%
State Street
11
State Street
Massachusetts
$1.75M -$1.79K -432 -0.1%
PCA
12
Peddock Capital Advisors
Massachusetts
$1.42M +$1.02M +245,728 +546%
Northern Trust
13
Northern Trust
Illinois
$1.07M +$149K +35,928 +20%
Charles Schwab
14
Charles Schwab
California
$1,000K +$214K +51,410 +34%
Morgan Stanley
15
Morgan Stanley
New York
$847K +$582K +140,094 +418%
Millennium Management
16
Millennium Management
New York
$768K -$1.6M -385,605 -71%
SSA
17
Schonfeld Strategic Advisors
New York
$760K +$109K +26,300 +20%
OCM
18
Osterweis Capital Management
California
$616K
KLC
19
Kent Lake Capital
Nevada
$570K -$2.62M -629,686 -84%
CIBC Asset Management
20
CIBC Asset Management
Ontario, Canada
$564K +$306K +73,737 +176%
Squarepoint
21
Squarepoint
New York
$473K -$126K -30,287 -24%
Bank of New York Mellon
22
Bank of New York Mellon
New York
$414K -$199K -48,004 -36%
WMSA
23
Weiss Multi-Strategy Advisers
New York
$249K -$37.4K -9,003 -15%
Renaissance Technologies
24
Renaissance Technologies
New York
$231K -$686K -165,200 -78%
ZIC
25
ZWJ Investment Counsel
Georgia
$220K -$415 -100 -0.2%

AKYA Hedge Fund Activity: Q4 2023 in Review

65 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Akoya BioSciences (AKYA) for Q4 2023, worth a combined $80.5M — up 7.5% from $74.9M a quarter earlier.

Buyers outnumbered sellers: 10 funds opened new AKYA positions and 7 closed out — a net gain of 3 holders — while 25 added to existing stakes and 21 trimmed.

The largest buyer was Peddock Capital Advisors, adding an estimated $1.02M. The largest seller was Kent Lake Capital, cutting an estimated $2.62M.

  • 65 institutional investors held Akoya BioSciences (AKYA) as of Q4 2023, up from 62 in Q3 2023.
  • Funds reported $80.5M of Akoya BioSciences stock for Q4 2023, up 7.5% quarter-over-quarter.
  • 10 funds opened new Akoya BioSciences positions in Q4 2023 and 7 closed out, a net change of +3 holders.
  • The largest Akoya BioSciences buyer in Q4 2023 was Peddock Capital Advisors, an estimated $1.02M added.
  • The largest Akoya BioSciences seller in Q4 2023 was Kent Lake Capital, an estimated $2.62M sold.

Based on aggregated 13F filings for Q4 2023.